Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Senores Pharmaceuticals Ltd. ( (IN:SENORES) ) is now available.
Senores Pharmaceuticals has informed Indian stock exchanges that it has submitted its annual disclosure under Regulation 31(4) of the SEBI Substantial Acquisition of Shares and Takeovers framework. The filing details encumbrances on company shares involving promoter Swapnil Jatinbhai Shah and the wider promoter group during the financial year ended March 31, 2026, underscoring ongoing compliance with public market transparency rules.
This disclosure indicates that security interests or similar encumbrances have been created on promoter-held shares, which can affect control dynamics and liquidity for investors. By formally recording these encumbrances with BSE and NSE, Senores Pharmaceuticals provides stakeholders clearer visibility into promoter share pledging and reinforces adherence to regulatory standards governing significant shareholdings.
More about Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals Limited is an India-based pharmaceutical company headquartered in Ahmedabad, Gujarat. The company is listed on both BSE and the National Stock Exchange of India under the symbol SENORES, and operates within the broader healthcare and drug manufacturing sector.
Average Trading Volume: 7,587
Technical Sentiment Signal: Buy
Current Market Cap: 42.04B INR
See more insights into SENORES stock on TipRanks’ Stock Analysis page.